SK Plasma Selected as Turkey’s Blood Product Partner... Joint Venture to Be Established

SK Plasma, a company specializing in blood products, has been selected as the technology export partner for Turkey's national strategy project aimed at achieving self-sufficiency in plasma fractionation products.

On November 24 (local time) in Ankara, Turkey, SK Plasma announced on November 25 that it had signed a “shareholders’ agreement” with the Turkish Red Crescent (the Red Crescent Society in Islamic countries) for the construction of a plasma fractionation plant and the establishment of the joint venture Proturk, in order to localize the production of nationally essential medicines.

SK Plasma's Andong Plant, responsible for the production of blood products. SK Plasma

The signing ceremony, which took place during the summit between the two countries, was attended by Kim Seungjoo, CEO of SK Plasma, and Fatma Meric Yilmaz, President of the Turkish Red Crescent.

President Lee Jaemyung stated in a joint press release, "We are very pleased that SK Plasma, a Korean company, will participate in Turkey’s project to achieve self-sufficiency in blood products."

Under this agreement, SK Plasma will receive technology transfer fees and acquire a 15% stake in Proturk. The remaining 85% will be held by Kizilay Yatirim, an investment company under the Turkish Red Crescent, and related government agencies.

The newly established joint venture Proturk will seek to build a plasma fractionation plant in the Cubuk area of Ankara, Turkey, with the capacity to process 600,000 liters of plasma annually.

This facility will produce albumin (ABM), used to supplement proteins in the blood; immunoglobulin (IVIG), used to treat patients with immune deficiencies; and factor VIII (FVIII), a blood coagulation factor essential for treating hemophilia A and other coagulation disorders.

SK Plasma will transfer plasma fractionation technology to Proturk and receive technology fees in stages.

The governments of both countries also plan to provide timely administrative and policy support, including securing the plant site and obtaining necessary permits during the project implementation. Jeong Yeondu, Korean Ambassador to Turkey, played a practical bridging role by actively coordinating through diplomatic channels.

Once the plant is completed, Turkey will be able to achieve self-sufficiency in plasma fractionation products. Blood products such as albumin are essential medicines used for surgical and emergency patients.

Fatma Meric Yilmaz, President of the Turkish Red Crescent, stated, "Collaboration with SK Plasma will be a significant milestone in securing sovereignty over essential medicines directly related to the health and lives of the Turkish people."

Kim Seungjoo, CEO of SK Plasma, said, "Building local infrastructure is a new business model that enhances the self-sufficiency of countries needing sovereignty over plasma fractionation products, while also ensuring stable demand."

This content was produced with the assistance of AI translation services.